Compare Johnson & Johnson (JNJ) vs ArcelorMittal SA (MT) Price & Performance

Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.

The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.

ArcelorMittal (MT) trades at $65.81, down 0.96% on the day but remains near its 52-week high of $72.50. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent developments include a strategic AI collaboration with AWS and ongoing share buybacks, while analyst sentiment is mixed with 50% recommending Buy.

Outlook: MT presents value with attractive P/E (17.4) and P/B (0.91) ratios, supported by rising net margins. Risks include declining revenue trends, high capital expenditures, and exposure to steel market volatility. The stock's upside depends on execution of expansion projects and stable commodity pricing.